Patricia Danzon, Forbes, Biotech
Assesses Most Important Evolving Biotech Trends
LDI Senior Fellow Patricia Danzon's assessment of the most important trends in biotech is the subject of an extensive Forbes article. The piece looks back at the record levels of biotech IPOs that occurred during 2013 and explores the prospects of their long-term success.
"There’s a huge amount of real uncertainty about the likely performance of some of these companies — scientific uncertainty about whether drugs will pan out in [late-stage] trials and market uncertainty as to how the products will be accepted,” said Danzon, PhD, and Professor of Health Care Management at the Wharton School. "There have been past booms that have ended up being bubbles, but with these early-stage companies, we may not know until the drugs succeed or fail on the market."